Enterprise Value

1.457B

Cash

307.6M

Avg Qtr Burn

N/A

Short % of Float

12.89%

Insider Ownership

2.04%

Institutional Own.

50.27%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Afrezza® (insulin human) Inhalation Powder Details
Diabetes, Type 1 diabetes, Type 2 diabetes

Phase 4

Data readout

Approved

Quarterly sales

Afrezza® (insulin human) Inhalation Powder Details
Type 1 diabetes, Type 2 diabetes, Diabetes

Phase 3

Data readout

Clofazimine inhalation suspension (MNKD 101) Details
Lung disease, Nontuberculous mycobacterial lung disease

Phase 3

Initiation

MNKD 201 (nintedanib DPI) Details
Lung disease, Idiopathic pulmonary fibrosis

Phase 1

Data readout